These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 12007851)
21. Susceptibility of Clinical Isolates of Sengyee S; Saiprom N; Paksanont S; Limmathurotsakul D; Wuthiekanun V; Chantratita N Am J Trop Med Hyg; 2017 Jul; 97(1):62-67. PubMed ID: 28719324 [No Abstract] [Full Text] [Related]
22. Diffusion and activity of antibiotics against Burkholderia pseudomallei biofilms. Pibalpakdee P; Wongratanacheewin S; Taweechaisupapong S; Niumsup PR Int J Antimicrob Agents; 2012 Apr; 39(4):356-9. PubMed ID: 22364716 [TBL] [Abstract][Full Text] [Related]
23. Resistance of Pseudomonas pseudomallei growing as a biofilm on silastic discs to ceftazidime and co-trimoxazole. Vorachit M; Lam K; Jayanetra P; Costerton JW Antimicrob Agents Chemother; 1993 Sep; 37(9):2000-2. PubMed ID: 7694545 [TBL] [Abstract][Full Text] [Related]
24. The antibiotics of choice for the treatment of melioidosis in Indian set up. Shaw T; Tellapragada C; Eshwara VK; Bhat HV; Mukhopadhyay C Indian J Med Microbiol; 2016; 34(3):353-4. PubMed ID: 27514960 [TBL] [Abstract][Full Text] [Related]
25. Rapid antimicrobial susceptibility testing and β-lactam-induced cell morphology changes of Gram-negative biological threat pathogens by optical screening. McLaughlin HP; Sue D BMC Microbiol; 2018 Dec; 18(1):218. PubMed ID: 30563467 [TBL] [Abstract][Full Text] [Related]
26. Correlation Between Etest and Reference Broth Microdilution for Antimicrobial Susceptibility Testing of Lonsway DR; Elrod MG; Kendrick N; Tiller R; Sullivan MM; Edwards JR; Blaney DD; Karlsson M Microb Drug Resist; 2020 Apr; 26(4):311-318. PubMed ID: 31596673 [TBL] [Abstract][Full Text] [Related]
27. [In vitro antibiotic susceptibility compliance with efficacy of chemotherapy in infections due to pathogenic Burkholderias]. Iliukhin VI; Senina TV; Trushkina MN; Shubnikova EV; Antonov IuV; Andropova NV Antibiot Khimioter; 2009; 54(7-8):19-23. PubMed ID: 20201399 [TBL] [Abstract][Full Text] [Related]
28. Antibiotic susceptibility of 50 clinical isolates of Burkholderia pseudomallei from Singapore. Sivalingam SP; Sim SH; Aw LT; Ooi EE J Antimicrob Chemother; 2006 Nov; 58(5):1102-3. PubMed ID: 16951412 [No Abstract] [Full Text] [Related]
29. Genomic and RT-qPCR analysis of trimethoprim-sulfamethoxazole and meropenem resistance in Burkholderia pseudomallei clinical isolates. Schnetterle M; Gorgé O; Nolent F; Boughammoura A; Sarilar V; Vigier C; Guillier S; Koch L; Degand N; Ramisse V; Tichadou X; Girleanu M; Favier AL; Valade E; Biot F; Neulat-Ripoll F PLoS Negl Trop Dis; 2021 Feb; 15(2):e0008913. PubMed ID: 33592059 [TBL] [Abstract][Full Text] [Related]
30. Reduced susceptibility of Malaysian clinical isolates of Burkholderia pseudomallei to ciprofloxacin. Liew FY; Tay ST; Puthucheary SD Trop Biomed; 2011 Dec; 28(3):646-50. PubMed ID: 22433895 [TBL] [Abstract][Full Text] [Related]
31. In-vitro activity of β-lactams/trimethoprim-sulfamethoxazole combinations against different strains of Burkholderia pseudomallei. Mohamad NI; Harun A; Hasan H; Deris ZZ Trop Biomed; 2022 Mar; 39(1):11-16. PubMed ID: 35225295 [TBL] [Abstract][Full Text] [Related]
32. Prevalence of bla(PenA) and bla(OXA) in Burkholderia pseudomallei Isolated from Patients at Sappasitthiprasong Hospital and Their Susceptibility to Ceftazidime and Carbapenems. Panya M; Thirat S; Wanram S; Panomket P; Nilsakul J J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S12-6. PubMed ID: 26817233 [TBL] [Abstract][Full Text] [Related]
33. Activity of Ceftolozane-Tazobactam against Slack A; Parsonson F; Cronin K; Engler C; Norton R Am J Trop Med Hyg; 2018 Aug; 99(2):281-282. PubMed ID: 29943711 [TBL] [Abstract][Full Text] [Related]
34. In vitro activities of amoxicillin-clavulanate, doxycycline, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole against biofilm of Brazilian strains of Burkholderia pseudomallei. Bandeira Tde J; Moreira CA; Brilhante RS; Castelo-Branco Dde S; Neto MP; Cordeiro Rde A; Rodrigues Tde J; Rocha MF; Sidrim JJ Antimicrob Agents Chemother; 2013 Nov; 57(11):5771-3. PubMed ID: 24002089 [TBL] [Abstract][Full Text] [Related]
35. Adaptation and antibiotic tolerance of anaerobic Burkholderia pseudomallei. Hamad MA; Austin CR; Stewart AL; Higgins M; Vázquez-Torres A; Voskuil MI Antimicrob Agents Chemother; 2011 Jul; 55(7):3313-23. PubMed ID: 21537012 [TBL] [Abstract][Full Text] [Related]
37. Cases of melioidosis in a university teaching hospital in Malaysia. Raja NS J Microbiol Immunol Infect; 2008 Apr; 41(2):174-9. PubMed ID: 18473106 [TBL] [Abstract][Full Text] [Related]
38. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. Sarovich DS; Price EP; Von Schulze AT; Cook JM; Mayo M; Watson LM; Richardson L; Seymour ML; Tuanyok A; Engelthaler DM; Pearson T; Peacock SJ; Currie BJ; Keim P; Wagner DM PLoS One; 2012; 7(2):e30789. PubMed ID: 22363490 [TBL] [Abstract][Full Text] [Related]
39. Antimicrobial resistance in Burkholderia pseudomallei. Vorachit M; Chongtrakool P; Arkomsean S; Boonsong S Acta Trop; 2000 Feb; 74(2-3):139-44. PubMed ID: 10674642 [TBL] [Abstract][Full Text] [Related]
40. Sensitive and specific molecular detection of Burkholderia pseudomallei, the causative agent of melioidosis, in the soil of tropical northern Australia. Kaestli M; Mayo M; Harrington G; Watt F; Hill J; Gal D; Currie BJ Appl Environ Microbiol; 2007 Nov; 73(21):6891-7. PubMed ID: 17873073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]